Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/9/2025

Treatment Guidelines for Acute Disseminated Encephalomyelitis (ADEM)

First-Line Treatment

  • The Infectious Diseases Society of America (IDSA) recommends high-dose intravenous methylprednisolone (1 g daily) for at least 3-5 days, followed by an oral corticosteroid taper over 4-6 weeks, for the treatment of ADEM 1
  • The IDSA specifically recommends methylprednisolone 1 g intravenously daily for at least 3-5 days for ADEM treatment 1

Critical Initial Management Considerations

  • Empirical antimicrobial therapy, including intravenous acyclovir, should be initiated immediately while awaiting diagnostic confirmation, as infectious encephalitis requires different treatment, according to the IDSA 1, 2

Steroid Tapering Protocol

  • The oral corticosteroid taper following pulse therapy should extend over 4-6 weeks minimum, to prevent symptom recurrence, as recommended by the IDSA 1, 2
  • If flaring occurs during the taper period, consider extending the taper duration or increasing the dose temporarily, as suggested by the Journal of Clinical Oncology 2

Second-Line Therapies for Inadequate Response

  • If patients respond poorly to corticosteroids after 3 days or have contraindications, proceed to intravenous immunoglobulin (IVIG) or plasma exchange, as recommended by the IDSA and the Journal of Clinical Oncology 1, 2
  • The IDSA notes successful treatment reports with plasma exchange, though randomized trial data are lacking 1
  • Important caveat: Plasmapheresis immediately after IVIG will remove the administered immunoglobulin, so timing matters, as noted by the Journal of Clinical Oncology 2

Treatment Algorithm for Severity-Based Management

  • For moderate cases (Grade 2), stop any immune checkpoint inhibitors, start prednisone 1 mg/kg daily, and taper over 1 month, as recommended by the Journal of Clinical Oncology 2
  • For severe cases (Grade 3-4), permanently discontinue immune checkpoint inhibitors, admit patient for inpatient care, and consider IVIG or plasmapheresis if no improvement or symptoms worsen after 3 days, as recommended by the Journal of Clinical Oncology 2
  • Taper steroids following acute management over at least 4-6 weeks, as recommended by the Journal of Clinical Oncology 2, 3

Additional Therapeutic Considerations

  • For patients with positive autoimmune encephalopathy or paraneoplastic antibodies, or those with limited improvement, consider rituximab in consultation with neurology, as recommended by the Journal of Clinical Oncology 2, 3
  • This represents a third-line option for refractory cases, and consultation with neurology is essential before initiating rituximab, as noted by the Journal of Clinical Oncology 2, 3

Common Pitfalls and Caveats

  • Do not delay empirical acyclovir, as the differential diagnosis includes herpes simplex encephalitis, which requires immediate antiviral therapy, as recommended by the IDSA and the Journal of Clinical Oncology 1, 2
  • Avoid premature steroid discontinuation, as the 4-6 week taper is critical, and shorter tapers may lead to symptom recurrence, as recommended by the IDSA and the Journal of Clinical Oncology 1, 2
  • Consider MOG antibody testing, as anti-myelin oligodendrocyte glycoprotein antibodies may influence treatment decisions and prognosis, as noted by the Journal of Neuroinflammation 4

Acute Disseminated Encephalomyelitis (ADEM) Diagnosis and Treatment

Definition and Classification

  • ADEM is defined as inflammation of the brain parenchyma that causes a syndrome of neurological dysfunction, often occurring as a post-infectious or post-vaccination autoimmune response 5, 6
  • ADEM is classified among the inflammatory demyelinating diseases of the central nervous system that can affect both brain and spinal cord 7

Epidemiology

  • ADEM predominantly affects children, with reported incidences of approximately 10.5 to 13.8 per 100,000 children in Western settings 5
  • In the UK, this translates to approximately 1-2 children per year in a typical district general hospital and 8-10 in a large tertiary children's hospital 5

Etiology

  • ADEM typically develops following a viral or bacterial infection (post-infectious ADEM) or vaccination (post-vaccination ADEM) 5, 7
  • Common infectious triggers include measles, mumps, rubella, varicella zoster, Epstein-Barr virus, cytomegalovirus, herpes simplex, hepatitis A, influenza, and enterovirus infections 8, 7
  • Vaccines that have been temporally associated with ADEM include those against anthrax, Japanese encephalitis, yellow fever, measles, influenza, smallpox, and rabies 8, 7

Clinical Presentation

  • Encephalopathy is a required component for diagnosis, ranging from confusion to coma 7
  • Multifocal neurologic deficits affecting various parts of the central nervous system are characteristic 7, 7
  • Common neurological manifestations include optic neuritis (often bilateral) 7, myelitis (frequently longitudinally extensive) 7, brainstem encephalitis 7, cerebellar ataxia 7, motor deficits 7, and seizures 7
  • Symptoms typically develop 1-14 days after vaccination or 1 week after the appearance of a rash in an exanthematous illness 8
  • Fever is usually absent at the onset of neurological illness 8

Diagnostic Evaluation

  • MRI is the imaging modality of choice, revealing characteristic findings such as large, confluent T2 hyperintense brain lesions, multifocal, subcortical white matter abnormalities, involvement of thalami and basal ganglia, longitudinally extensive spinal cord lesions, and perioptic enhancement during acute optic neuritis 7
  • CSF analysis typically shows lymphomonocytic pleocytosis, elevated protein levels, normal glucose levels, and oligoclonal bands may be absent or transient (unlike in multiple sclerosis) 7
  • Diagnostic criteria require exclusion of other conditions that can mimic ADEM 6, 7

Differential Diagnosis

  • Infectious encephalitis (viral, bacterial, fungal, parasitic) 5, 6
  • Antibody-associated encephalitis (e.g., anti-NMDA receptor encephalitis) 5
  • Metabolic encephalopathies 5
  • Toxic encephalopathies 5

Treatment

  • First-line treatment is high-dose intravenous methylprednisolone, followed by oral corticosteroid taper over 4-6 weeks 7
  • Symptoms may flare during steroid tapering, suggesting steroid-dependence in some cases 7